Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-192.4%-343.6%9.1%
Net margin-154.9%-282.8%21.9%
EBITDA margin-190.4%-340.9%9.6%
Returns
Return on equity-17.1%-20.2%7.8%
Return on assets-15.9%-18.4%7%
Return on invested capital-27.6%-29.1%3.8%
Efficiency
Asset turnover0.1×-0.2×0.1×-0.7×0.3×-0.4×0.3×-0.4×0.3×-0.4×
Liquidity
Current ratio17.8×+0.5×12.7×+0.2×13×+2.4×17×+3.2×17.3×+1.5×
Quick ratio17.8×+0.5×12.7×+0.2×13×+2.4×17×+3.2×17.3×+1.5×
Cash ratio5.6×+1.6×2.8×+0.8×2.5×-0.4×4.7×-3.8×-0.3×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$9.30-15.0%$9.67-6.8%$10.12+17.5%$10.52+19.1%$10.94+24.2%
Valuation
Market capitalization$6.73B+127%$5.46B+137%$4.13B+49.8%$3.33B+57.8%$2.97B+68.6%
Enterprise value$6.54B+130%$5.34B+141%$4.03B+52.7%$3.17B+79.7%$2.84B+78.8%
Price / sales90.8×+76.5×118.7×+113×19.8×+11.2×15.9×14.3×
Price / book10.3×+6.0×8.9×+5.5×6.4×+1.2×+1.1×4.3×+1.2×
EV / sales88.3×+74.7×116.1×+111×19.3×+11.1×15.2×13.7×
Earnings yield-1.7%-2.4%1.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Protagonist Therapeutics's ratios come from?
Every ratio is computed from Protagonist Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.